跳至主要内容
临床试验/KCT0007196
KCT0007196招募中未知

Effect of blood pressure variability and nocturnal hypertension on hypertension-mediated organ damage and cardiovascular disease in elderly patients with hypertension

Chungbuk National University Hospital0 个研究点目标入组 1,300 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
1,300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
65?(Year) 至 o Limit(—)
性别
All

入选标准

  • Patients aged 65 or older with hypertension and enrolled in the target blood pressure study (HOWOLD-BP trial, 2018-09-015) among elderly hypertension subjects who voluntarily participated in this clinical trial and agreed to participate in the study.

排除标准

  • It is the same as the exclusion criteria of the study on prognosis analysis according to target blood pressure when treating hypertension in elderly hypertension subjects (HOWOLD-BP trial, 2018-09-015). Patients who meet any of the following criteria cannot participate in this clinical trial.
  • 1) Subjects with all suspected history of secondary hypertension, such as aortic stenosis, hyperaldosterone, renal stenosis, cushing disease, chromium-friendly cytoma, and polycystic nephrotic disease, and all suspected of secondary hypertension.
  • 2) Resistant hypertension subjects whose blood pressure is controlled to less than 140/90 mmHg using three or more antithrombotic drugs, including diuretics, or four or more antithrombotic drugs including diuretics, with blood pressure controlled to less than 140/90 mmHg.
  • 3) Subjects with orthostatic hypotension (One minute standing SBP < 110 mmHg) accompanied by symptoms at the time of screening
  • 4) Subject to uncontrolled diabetes whose HbA1C value is defined to be 10% or higher at the time of screening.
  • 5) Subject to chronic kidney disease with maintenance dialysis or estimated GFR 1515 mL/min/1.73 m2
  • 6) Subjects who have undergone acute coronary syndrome, heart surgery, and urgent percutaneous coronary intervention (PCI) within the last 3 months.
  • 7) Subject to systolic heart failure with a left ventricular uvula rate of less than 40% in the past history.
  • 8) Subjects with hypertrophic obstructive cardiomyopathy, aortic stenosis, severe valve disease, and hemodynamically significant congenital heart disease.
  • 9) Subject to acute stroke diagnosed with stroke within the last 3 months.
  • 10) Subjects with known moderate or malignant retinopathy such as retinal bleeding, vision impairment, and retinal microarachnoid within the last 6 months.
  • 11) Subjects who have clinically significant liver disease or whose AST/ALT level is 3 times or more than the normal upper limit.
  • 12) Uncontrolled thyroid function.
  • 13) Those who participated in other clinical trials within 4 weeks of screening or those who plan to participate in other clinical trials during this intervention study.
  • 14) If there are other serious reasons for restricting participation and progress in research at the discretion of the researcher

研究者

相似试验